Article Details
Retrieved on: 2022-04-14 14:21:42
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... still responding at 12 months, beating Stifel analysts' 70% “bull case” and coming in substantially higher than Roche's Ros1 agent Rozlytrek.
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here